glutathione s transferase sequence pgex pC6-2/caspase-6 system to purify glutathione-S-transferase-free recombinant fusion proteins expressed in Escherichia coli Glutathione S-transferase π: a potential

Description

To harness this GVL effect, a number of approaches to prevent relapse after transplant have been studied, including withdrawal of immune suppression or donor lymphocyte infusion and targeted immunotherapies, such as monoclonal antibodies and natural killer cell therapy.[138,139] Trials in Europe and the United States have shown that patients defined as having a high risk of relapse based on increasing recipient chimerism (i.e., increased percentage of recipient DNA markers) can successfully undergo withdrawal of immune suppression without excessive toxicity.[140,141] One study showed that in 46 patients with increasing recipient chimerism, the 31 patients who underwent immune suppression withdrawal, donor lymphocyte infusion, or both therapies had a 3-year EFS rate of 37% versus 0% in the nonintervention group ( P 5% bone marrow blasts, CNS3 disease [defined as cerebrospinal fluid specimen with 5 white blood cells/L with lymphoblasts and/or the presence of cranial nerve palsies], or non-CNS extramedullary disease [EMD]) was associated with inferior outcomes.[192] Patients with a high-disease burden had poorer outcomes (12-month OS rate, 58%